Clinical trials: Asthma Patients
Asthma
A Clinical Study of Oglemilast in Patients With Mild to Moderate Persistent Asthma
The study is aimed at evaluating efficacy and safety of oglemilast in the treatment of stable mild to moderate persistent asthma. The study involves two weeks of run in period. This is a placebo controlled study.
- Trial name
- NCT00859404
- Testing
- oglemilast
- Where
- India
- Volunteers
- 282 people
- Sponsor
- Glenmark Pharmaceuticals Europe Ltd. (R&D)
Asthma
Clinical Study to Explore the Efficacy of ACT-129968 in Patients With Partly Controlled Asthma
This study will assess the efficacy and safety of ACT-129968 in subjects with partly controlled asthma on reliever therapy only.
- Trial name
- CONTROL (NCT01225315)
- Testing
- Setipiprant
- Where
- 97 sites in United States, Australia and 11 more
- Volunteers
- 438 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Asthma
Study to Investigate the Efficacy of Symbicort® SMART.
The primary objective of this study is to compare the efficacy of Symbicort SMART (Symbicort Turbuhaler 160/4.5μg, one inhalation twice daily plus as needed) with Symbicort Turbuhaler 160/4.5μg, one inhalation twice daily plus…
- Trial name
- SAKURA (NCT00839800)
- Testing
- Symbicort Turbuhaler, Terbutaline Turbuhaler
- Where
- 109 sites in Argentina, Brazil and 10 more
- Volunteers
- 2,091 people
- Sponsor
- AstraZeneca
Asthma
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
The purpose of the study was to assess the clinical effect of QAW039 in non-atopic asthmatics taking low dose Inhaled Corticosteroid (ICS) as background therapy.
- Trial name
- NCT01836471
- Testing
- QAW039, Fluticasone 250 mcg, Fluticasone 100 mcg
- Where
- 76 sites in United States, Belgium and 8 more
- Volunteers
- 345 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma
Treatment, Randomised, Double Blind, Parallel Assignment, Safety/efficacy Study
- Trial name
- NCT00843193
- Testing
- INTRAVENOUS GSK679586, FLUTICASONE PROPIONATE
- Where
- 35 sites in United States, France and 6 more
- Volunteers
- 198 people
- Sponsor
- GlaxoSmithKline
Severe Asthma
PROPE Severe Asthma Study in Egypt
Asthma is a syndrome characterized by airway inflammation, reversible airway obstruction, and airway hyper-responsiveness. Patients present clinically with recurrent wheezing, shortness of breath, cough, and chest tightness.
- Trial name
- NCT06283290
- Where
- 4 sites in Egypt
- Volunteers
- 201 people
- Sponsor
- AstraZeneca
Asthma
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
This is a Phase 2a, multicentre, randomised, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy, safety and PK of AZD4604 administered BID using a dry-powder inhaler at one dose level over a 12-week…
- Trial name
- AJAX (NCT06020014)
- Testing
- AZD4604
- Where
- 124 sites in United States, Argentina and 16 more
- Volunteers
- 339 people
- Sponsor
- AstraZeneca
Allergic Rhinoconjunctivitis
Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense
Based on EMA (European Medicines Agency) new guidelines on the clinical development of products for immunotherapy for the treatment of allergic diseases the aim of this study is to establish a dose-response relationship for…
- Trial name
- NCT01567306
- Testing
- Allergovac Depot
- Where
- 10 sites in Portugal, Spain
- Volunteers
- 151 people
- Sponsor
- Roxall Medicina España S.A
Asthma
Cross-sectional Study for Identification and Description of Severe Asthma Patients
This will be a non-drug interventional cross-sectional study, where the screening visit and study visit can occur on the same day. Investigational product will not be administered.
- Trial name
- NCT02293265
- Testing
- Short Acting Beta Agonist (SABA)
- Where
- 74 sites in United States, Australia and 4 more
- Volunteers
- 767 people
- Sponsor
- GlaxoSmithKline
Asthma
Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma
This is a study designed to evaluate efficacy and safety of Benralizumab in reducing the Oral Corticosteroid (OCS) use in adult patients with severe asthma who are receiving OCS with or without additional asthma controller…
- Trial name
- PONENTE (NCT03557307)
- Testing
- Benralizumab
- Where
- 144 sites in United States, Argentina and 15 more
- Volunteers
- 598 people
- Sponsor
- AstraZeneca
Asthma
Change in Patient-Reported Outcomes in Severe Eosinophilic Asthma Patients Treated With Benralizumab Under Real-life Conditions
The main aim of this study is to investigate the change in asthma control after 6 months of therapy in patients treated with benralizumab biologic therapy for severe eosinophilic asthma under real-life conditions in a pulmonary…
- Trial name
- imPROve (NCT04184284)
- Where
- 50 sites in Germany
- Volunteers
- 246 people
- Sponsor
- AstraZeneca
Asthma
Montelukast Post-marketing Comparative Study With Theophyline Added to Inhaled Corticosteroid (0476-396)
A clinical study explores the safety and efficacy of montelukast and to compare the safety and efficacy of montelukast with those of theophylline in pediatric bronchial asthma patients when they are used in conjunction with…
- Trial name
- NCT00756418
- Testing
- montelukast, Theophylline
- Volunteers
- 84 people
- Sponsor
- Organon and Co
Asthma
Single Dose Study of GSK1440115 in Patients With Asthma
The purpose of this study is to assess bronchodilator effect after single dose administration of GSK1440115 in a population of mild to moderate asthmatic patients.
- Trial name
- NCT01424280
- Testing
- 1440115
- Where
- Australia
- Volunteers
- 12 people
- Sponsor
- Accenture
Asthma
Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled Asthma
The purpose of this study is to evaluate the efficacy, safety and tolerability of JNJ-39758979 compared with placebo in patients with uncontrolled asthma despite current treatment with inhaled corticosteroids and/or long-acting…
- Trial name
- NCT01493882
- Testing
- JNJ-39758979 30 mg/d, JNJ-39758979 100 mg/d, JNJ-39758979 300 mg/d
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Persistent Asthma
Efficacy, Safety, and Pharmacokinetics of QAW039
This study will assess the safety, efficacy and pharmacokinetics of QAW039 in steroid-free patients with mild to moderate persistent asthma.
- Trial name
- NCT01253603
- Testing
- QAW039 capsules once daily for 28 days, Fluticasone propionate inhaler twice daily for 28 days
- Where
- 26 sites in United States, Belgium and 3 more
- Volunteers
- 170 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA
Evaluate the superiority of CHF 5993 100/6/12.5 µg Pressurised Metered Dose Inhaler (pMDI) (fixed combination of extrafine beclometasone dipropionate (BDP) plus formoterol fumarate (FF) plus glycopyrronium bromide [GB]) versus…
- Trial name
- TRIMARAN (NCT02676076)
- Testing
- CHF 5993 100/6/12.5, CHF 1535 100/6 µg
- Where
- Germany
- Volunteers
- 1,155 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Single Dose Study of the Fluticasone/Salmeterol (500/50 μg) Administered With Elpenhaler® Versus Diskus®
The aim of this study is to establish the therapeutic equivalence between the test (Fluticasone/Salmeterol administered with Elpenhaler®, Rolenium®) and the reference formulation (Seretide®, administered with Diskus®), both…
- Trial name
- NCT01484210
- Where
- 5 sites in Czechia
- Volunteers
- 28 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Asthma
Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma
This was a randomized, placebo-controlled, double-blind, six-sequence, three-period cross-over study in asthma patients. The study consisted of a 14-day screening period, followed by a 14-day run-in period, and a treatment epoch…
- Trial name
- QVM149 (NCT03108027)
- Where
- 7 sites in Germany, Netherlands and 1 more
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
The primary objective of this study is to determine the effect of reslizumab (110 mg) administered subcutaneously every 4 weeks on clinical asthma exacerbations in adults and adolescents with asthma and elevated blood eosinophils…
- Trial name
- NCT02452190
- Testing
- Reslizumab
- Where
- 226 sites in United States, Argentina and 19 more
- Volunteers
- 468 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.